The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their suppression of HBV replication, but the treatments rarely eradicate HBV from individuals. Simil...

Full description

Bibliographic Details
Main Authors:	Philippe Gallay, Daren Ure, Michael Bobardt, Udayan Chatterji, James Ou, Daniel Trepanier, Robert Foster
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0217433

Similar Items

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
by: Philippe A Gallay, et al.
Published: (2015-01-01)

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
by: Michael Bobardt, et al.
Published: (2020-01-01)

In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B
by: Daniel J. Trepanier, et al.
Published: (2017-11-01)

Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System
by: Daniel J Trepanier, et al.
Published: (2018-11-01)

Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.
by: Edouard Tuaillon, et al.
Published: (2012-01-01)

Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
by: Romina Salpini, et al.
Published: (2020-02-01)

HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01)

Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
by: Jing Cao, et al.
Published: (2020-01-01)

Clinical features of HBsAg-negative HBV-related hepatocellular carcinoma
by: MA Yan, et al.
Published: (2017-04-01)

Correlation between HBsAg quantitation and HBV DNA in HBeAg-Negative HBV/D patients
by: Anouar Teriaky, et al.
Published: (2013-01-01)

HBV感染者HBsAg和抗-HBs双阳性发生机制
by: REN Meixin
Published: (2014-04-01)

PROPORTION OF HBsAg AND HBeAg POSITIVE IN MATERNAL PATIENTS AND THEIR HBsAg POSITIVES BABIES WITH IMMUNOPROPHYLAXIS OF HBV IMMUNIZATION IN Dr. SOETOMO GENERAL HOSPITAL, SURABAYA
by: Melina Rosita Tanadi, et al.
Published: (2017-08-01)

Is Quantitative HBsAg Measurement a Reliable Substitute for HBV DNA Quantitation?
by: Mohammad Reza Mahdavi, et al.
Published: (2015-07-01)

HBV DNA Positive Rate in HBsAg-negative Blood Donations by NAT
by: Ruoh-Ing Yang, et al.
Published: (2006)

LDH-isoenzymes and HBsAg.
by: Bharucha Z, et al.
Published: (1980-04-01)

Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients
by: Xian-ding Wang, et al.
Published: (2021-01-01)

Using the Quantitative Determination of HBsAg to Monitor the Natural History of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-09-01)

Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-04-01)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
by: Robert L. Kruse, et al.
Published: (2017-12-01)

Evolution of HBsAg Mutants in Serum During Chronic HBV Infection:The Virologic Implications
by: Wen-Chi Chen, et al.
Published: (2000)

Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
by: Akif Altinbas, et al.
Published: (2012-05-01)

HBsAg loss with HBsAg/anti-HBs seroconversion and non-detectable HCV-RNA in a patient with chronic HBV e-minus/HCV hepatitis treated with two cycles of antiviral therapy
by: Antonio Salvio, et al.
Published: (2012-01-01)

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia
by: Crozier Sarah, et al.
Published: (2008-04-01)

Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies
by: Tai-Cheng Zhou, et al.
Published: (2017-04-01)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.
by: Zhenhuan Cao, et al.
Published: (2020-01-01)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
by: Zhenhuan Cao, et al.
Published: (2020-10-01)

IL-10 Promoter Polymorphism Distribution among HBsAg-Reactive and HBsAg-Nonreactive Blood Donors
by: Rahmat Azhari Kemal, et al.
Published: (2020-03-01)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
by: Lin Zhang, et al.
Published: (2020-01-01)

A Study of Small Hepatitis B Surface Antigen (HBsAg) in the HBsAg Particle and HDV Formation
by: Chuan Jen Wang, et al.
Published: (2000)

Transgenic lettuce seedlings carrying hepatitis B virus antigen HBsAg
by: Jackson Marcondes, et al.

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
by: Murat Afyon
Published: (2016-05-01)

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
by: Pierre Gantner, et al.
Published: (2019-01-01)

Value of HBsAg level in dynamic monitoring of disease progression in patients with chronic HBV infection
by: BAO Teng, et al.
Published: (2017-08-01)

Production of Recombinant HBsAg-Interleukin-2 Fusion Protein to Overcome MHC-Restricted Nonresponsiveness to HBsAg Vaccine
by: Guo, Shiu-Ping, et al.
Published: (1998)

Evaluating sterilizing filtration for API-HBsAg
by: Alejandro Beldarraín, et al.

Study of HBsAg-interaction protein: -glucosidase
by: Chao-wen Yen, et al.
Published: (2003)

Characterization of the HBsAg-resisted Yeast Saccharomyces
by: Pan, Jain Ting, et al.
Published: (1995)

Geographic distribution of HBsAg subtypes in Brazil Distribuição geográfica dos subtipos de antígenos de HBsAg no Brasil
by: Ana Maria Coimbra Gaspar, et al.
Published: (1987-06-01)

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets
by: Luna Colagrossi, et al.
Published: (2018-07-01)